Trump blocks Taiwan's president from New York stopover
's administration has denied permission for
Taiwan
's President Lai Ching-te to stop in
New York
en route to Central America, after
China
raised objections with Washington about the visit.
Mr Lai planned to travel to the US in August en route to Paraguay, Guatemala and Belize, which recognise Taiwan as a country. But the US told Mr Lai he could not visit New York on the way, according to three people familiar with the decision.
On Monday in Taipei, Mr Lai's office issued a statement saying he had no plans to travel overseas in the near future because Taiwan was recovering from a recent typhoon and Taipei was in talks with the US about
tariffs
.
The people familiar with the matter said his decision not to travel came after he had been told he would not be allowed to visit New York.
READ MORE
The White House's decision will deepen concerns among Taiwan's supporters in Washington that Mr Trump is taking a softer stance on China as he pushes to hold a summit with President
Xi Jinping
.
The Financial Times reported on Monday that the US commerce department had been told to freeze planned export controls against China as the countries hold trade talks and discuss a summit.
China objects to Taiwanese leaders visiting the US, which does not have official diplomatic relations with Taipei. In 2023, the Biden administration allowed then-president Tsai Ing-wen to stop in New York on her way to Belize and Guatemala.
Mr Lai had approached the Heritage Foundation, a conservative think tank in Washington, to host him at an event in New York during his proposed trip, according to a person familiar with the matter.
Mr Lai also planned to visit Dallas on his trip. It was unclear if the US only denied permission to visit New York or whether he was told he could not travel through the US at all. A senior US official said both sides were 'working to remedy the situation' and that no trip had been cancelled.
The Taipei Economic and Cultural Representative Office in Washington, which serves as the de facto embassy, referred to the statement from Mr Lai's office that he 'currently has no plans for overseas visits in the near future'.
Bonnie Glaser, a China and Taiwan expert at the German Marshall Fund, said the US decision suggested that 'Trump wants to avoid irritating Beijing while US-China negotiations are ongoing and planning gets under way for a possible summit with Xi Jinping'.
Ms Glaser said the decision recalled events in Mr Trump's first term when he delayed arms sales to Taiwan and 'went ballistic' after Alex Wong, a senior state department official who served as deputy national security adviser early in this administration, visited Taiwan to give remarks at a conference.
'Trump should be standing up to People's Republic of China pressure, not caving into it,' Ms Glaser said. 'By signalling that aspects of the US relationship with Taiwan are negotiable, Trump will weaken deterrence and embolden Xi to press for additional concessions regarding Taiwan.'
Several people familiar with the debate said the Trump administration was trying to avoid jeopardising trade talks with China. Treasury secretary Scott Bessent and Chinese vice-premier He Lifeng started a third round of negotiations in Stockholm on Monday.
The Trump administration has also held back taking tough actions against China after Beijing in May slowed the export of rare earths to the US, using its dominance in the industry as leverage against Washington.
Randy Shriver, a former senior US official who serves as chair of the board of the Institute for Indo-Pacific Security, said the decision to block Mr Lai from visiting New York reminded him of previous periods when the US avoided taking actions related to Taiwan that it believed would upset Beijing.
'If this is a result of the administration trying to curry favour with Beijing, it is a mistake,' Mr Shriver said. 'This is the old playbook, 'tyranny of the calendar', where there is never a good time to do something on Taiwan. You box yourself in.'
Rush Doshi, a former National Security Council China official, said it was important to see the Taiwan move in the context of an across-the-board softening of policy towards China ahead of a possible summit with Xi.
'They've frozen export controls and possibly financial actions too, approved the sale of powerful AI chips to China for nothing in return, and throttled the unofficial relationship with Taiwan,' said Mr Doshi, an assistant professor at Georgetown University and a senior fellow at the Council on Foreign Relations.
'What will they do when Beijing pockets this and asks for more, like changing Taiwan policy or demanding even better US technology?'
In addition to concerns about derailing a summit, some officials say the US needs to 'hide and bide' with respect to China. The phrase – which was used by China's former paramount leader Deng Xiaoping – is being invoked to explain that the rare earths leverage China has created over the US limits Washington's ability to take tough actions against Beijing. – Copyright The Financial Times Limited 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Examiner
2 hours ago
- Irish Examiner
Trump's global tariff agenda puts Ireland's pharmaceutical industry at serious risk
The whole world is in thrall to the whims of Donald Trump's tariff agenda, as it has been since the 47th president of the United States' swearing-in last January. We've learned a few uncomfortable truths along the way. Much of the early outcry from America's allies and trading partners surrounded the lack of economic logic to the imposition of tariffs – which are effectively a tax for Americans on foreign products, in theory making them less attractive to US consumers and heightening the allure of their own domestic suppliers. Critics said that the new regime would disrupt the world economy needlessly and perhaps bring about a global recession. That may well come to pass. The problem is that in this stand-off America has the greater wherewithal in terms of raw economic power. It holds the cards as Trump himself might say. And nations worldwide are beginning to fall into line, the EU just the latest after agreeing to a blanket 15% tariff on goods and services going forward. After President of the European Commission Ursula von der Leyen and US President Donald Trump agreed the trade deal, the spin is that the pain of those tariffs is worth it in order to avoid a global trade war. Also, 15% is better than 30% or worse, is the thinking. Photo:The spin is that the pain of those tariffs is worth it in order to avoid a global trade war. Also, 15% is better than 30% or worse, is the thinking. Whether that represents capitulation in the face of bullyboy tactics, given that little or nothing has been asked of the US in return, is a separate conversation. Ireland's pharmaceutical industry Here in Ireland we have a bigger problem though, and that problem is the pharmaceutical industry. That industry contributes massively to the economy here via billions of euro in corporation tax contributions, with about 90 companies employing 50,000 people in highly-paid roles. A total 30,000 of those jobs are with American firms. Should foreign pharmaceutical concerns exit Ireland the impact on the country would be catastrophic. The industry globally had pleaded with Trump for it to be exempted from any tariff regime, ostensibly for altruistic reasons – that lifesaving medicines shouldn't be subject to capricious taxation. At an EU level, the industry asked that the bloc not apply reciprocal tariffs, one wish that has at least been granted. Pfizer is one of the massive American pharmaceutical companies holding bases in Ireland, in this case Cork. File picture: Dan Linehan Oddly enough, in Trump's world of permanent grievance where everyone has been making a sucker of the United States for decades, the outsize presence the US pharmaceutical industry holds in Ireland is one situation on which he indisputably has a legitimate point. Drug prices in the US can retail for as much as five times what an EU citizen would pay. Meanwhile, American pharma firms make a pretty penny avoiding American tax by basing themselves here. Trump's protectionist agenda demands that those jobs and companies should return home. The Government has been worrying about and planning for a worst-case scenario in terms of tariffs on pharmaceuticals for months. Reaction from the pharma companies But what of the pharma industry itself? The official line from the Irish Pharmaceutical Healthcare Association (IPHA), the industry's lobby group here, is that it is reviewing the announcements coming out of Washington as and when they happen 'as key implications for the pharmaceutical sector remain uncertain'. A stance it's hard to argue with given the whole world has grown used to the haphazard nature of the Trump administration's demands. The European Federation of Pharmaceutical Industries and Associations (EFPIA) notes that tariffs are 'a blunt instrument that will disrupt supply chains, impact on investment in research and development, and ultimately harm patient access to medicines on both sides of the Atlantic'. It added that if the goal is to rebalance trade and ensure a 'fairer distribution' of how pharmaceutical innovation is financed, then 'there are more effective means than tariffs that would help'. Impact on pharma in Ireland The IDA, the body with prime responsibility for attracting foreign investment to Irish shores, says of the pharma implications that it 'welcomes' the deal made between Europe and the US, arguing it provides 'much-needed certainty for Irish, European and American businesses who together represent the most integrated trading relationship in the world'. 'We are very much reliant (on the US market), there's no arguing with that,' says one industry insider. Last year a massive €44bn in pharmaceutical products were exported directly from Ireland to the US. 'But when you stand back €100bn was exported globally. So half went to America, but it's not like all business went there, though it is certainly the biggest partner,' says the source. That doesn't mean that those massive American companies holding bases here – MSD, Pfizer, ELI Lilly, Johnson and Johnson etc – are about to up sticks on the back of the new tariff regime. 'They are not going to leave today or tomorrow, no. But it could definitely impact future investment decisions,' the source says. One of the problems is that a great deal of uncertainty still surrounds the 15% tariff agreement, particularly with regard to pharma. One of the Eli Lilly production buildings at its state-of-the-art facility in Dunderrow, Kinsale, Co Cork. For starters, most people concerned thought that the pharmaceutical industry wasn't to be included in the deal. Then about two hours after the deal was agreed European Commission president Ursula von der Leyen said it would be included, a point Trump appeared to back up. The following day the White House produced a 'fact sheet' describing how the new regime would work, and affirming the 15% rate for pharma. Except that the same sheet stated that the European Union would pay the tariff – which isn't how tariffs work. Then there is the Section 232 investigation which the US Department of Commerce initiated into the pharma industry in April – aiming to establish if how the pharmaceutical system worldwide currently functions impacts negatively on the US from a national security standpoint. Should the answer arrived at be a 'yes', then additional tariffs on pharma may well follow (such investigations typically take a minimum of six months to conclude, so we'll probably get an answer sometime towards the end of the year). 'Pharma plans in the long-term,' says Aidan Meagher, tax partner specialising in life sciences with consultants EY, noting that most pharma manufacturers will have been planning for this scenario for months and will have frontloaded stock into the American market, thus negating immediate impacts in the near term. He says that companies will be likely looking at 'dual sourcing' initiatives, supplying the American market from within the US itself and using Irish operations for its trade around the rest of the globe. 'Ireland needs to up its game' But Meagher says that it would be 'remiss' of Ireland, and the pharma industry here, to take a 'wait and see' approach, perhaps with the supposition that Trump's policies will last for the remaining three-and-a-half years of his term, and no longer. 'It is all about the next investment. A lot of these drugs only have patent protection for a certain life or longevity. Ireland needs to maintain investment and to incentivise the right kind of activity in terms of attracting that innovation,' he says. That means thinking outside the box in terms of tax credits for research and development, and improvements to infrastructure, particularly housing, Meagher says, areas in which we are notably lagging behind in terms of international competition. But he argues that the situation is far from a doomsday scenario. 'It's not as simple as that, it's a whole range of business factors that need to be considered – it's all about impacts for specific companies,' he says. 'It's not all necessarily doom and gloom. Companies have had plenty of time to consider this. And pharma companies are long-term thinkers. Ireland has had just two issues with the FDA (the US food and drug administration, responsible for approving new drugs) in its history. "The country has a strong reputation. These countries have invested significantly and Ireland is the owner of a lot of valuable intellectual property.' But it's certainly not a time to be complacent, Meagher argues. 'We have dropped down the competitiveness radar, and our competitors now aren't in the EU – they're in Switzerland, Singapore and the US itself. We need to be a top competitor for inward investment, and R&D and infrastructure will be critical. That is where Ireland needs to up its game.'
Irish Times
3 hours ago
- Irish Times
Data credibility fears fuelled after Trump orders firing of labour official
Sharp downward revisions to jobs data on Friday, followed by Donald Trump 's sudden order to fire the head of the Bureau of Labor Statistics , stoked investor fears about the integrity of economic data and the Fed's ability to read the true state of the US economy. News of a surprise weakening in the US labour market last month jolted investors, while revisions to job figures for the past two months raised worries the US central bank may have been flying blind in recent months and may need to play catch-up with interest rate cuts, investors said. Fed governor Adriana Kugler's early resignation from her term on Friday also potentially shakes up what was already a fractious succession process for Fed leadership amid difficult relations with Mr Trump. The US president on Friday renewed his call for Federal Reserve chair Jerome Powell to resign. 'Powell should resign, just like Adriana Kugler, a Biden Appointee, resigned,' Mr Trump said in a post on Truth Social. READ MORE 'Kugler's resignation allows the president to further shape the FOMC [Federal Open Market Committee] in his own image,' said Jamie Cox, managing partner at Harris Financial Group. Nonfarm payrolls increased by 73,000 jobs in July after rising by a downwardly revised 14,000 in June, the Labor Department's Bureau of Labor Statistics said in its employment report on Friday. Economists polled by Reuters had forecast payrolls increasing by 110,000 jobs after rising by a previously reported 147,000 in June. The report comes two days after the US central bank left unchanged its benchmark interest rate and avoided signalling imminent rate cuts, dialling back market expectations for an easing at the next policy meeting in September. That changed dramatically on Friday, with odds for a 25 basis point cut in September jumping to about 81 per cent after the data from 38 per cent on Thursday, according to CME Group data. 'The Fed's job is becoming increasingly difficult based on the deterioration of the economic data,' said Matthew Miskin, co-chief investment strategist at Manulife John Hancock Investments. 'These revisions are massive and really are a game changer to the Fed's reaction function, and so I think this Fed meeting is one that they'd like to revise.' Mr Trump on Friday said, without evidence, that numbers contained in the July jobs report from the Bureau of Labor Statistics were rigged. 'In my opinion, today's Jobs Numbers were RIGGED in order to make the Republicans, and ME, look bad,' Trump said in a Truth Social post. He ordered that the commissioner of the Labor Department's Bureau of Labor Statistics Erika McEntarfer be fired after the data release. 'It's definitely a case of shooting the messenger,' said Dean Smith, chief strategist at FolioBeyond. 'Firing the head of BLS is not going to improve data collection and dissemination ... it's going to undermine confidence in the data going forward,' he said. Revisions for May and June came in well above the norm, the Bureau of Labor Statistics said. It gave no reason for the revised data but noted that 'monthly revisions result from additional reports received from businesses and government agencies since the last published estimates and from the recalculation of seasonal factors.' May's nonfarm payroll gain was slashed by 125,000, from 144,000 to just 19,000, while June's downward revision was by 133,000. In total, employment over the two months is now 258,000 lower than initially reported. 'It is painfully obvious that the US government has an improper model for payroll calculations,' said Michael Green, portfolio manager at Simplify Asset Management. 'If you don't have reliable data, you make bad policy.' Spencer Hakimian, founder of macro hedge fund Tolou Capital Management, said lay-offs across several government departments, part of Mr Trump's plans to reduce wasteful government spending, have prompted him to rely more heavily on alternative measures of economic strength than just government data, such as credit card data, and data from Truflation, an independent inflation index alternative to official government inflation measures. Mr Powell said in a press conference on Wednesday the labour market remained strong, and that the central bank was still in the early stages of grasping how Mr Trump's overhaul of import taxes and other policy shifts would play out for inflation, employment and economic growth. 'Had those figures been the initial prints a month or two ago it would have significantly changed the labour market narrative over the entire summer,' said Adam Hetts, global head of multi-asset and portfolio manager at Janus Henderson Investors, in a note. Treasury yields, which move inversely to bond prices, dropped on Friday, with benchmark 10-year yields down by a whopping 15 basis points to 4.22 per cent – their biggest daily drop since April. Two-year yields were down by about 25 basis points to 3.69 per cent, registering their biggest daily decline since August last year. Stocks declined too, also weighed on by Mr Trump's latest tariffs salvo. The benchmark S&P 500 index lost 1.6 per cent, bringing stocks to their lowest since early July. The deterioration in the labour picture comes amid steep US tariffs on large trade partners that – while not as high as feared earlier this year – are still largely expected to worsen inflation and slow economic activity. (c) Copyright Thomson Reuters 2025
The Journal
4 hours ago
- The Journal
US to deploy two nuclear submarines in response to 'highly provocative' comments from Russia
LAST UPDATE | 3 hrs ago US PRESIDENT DONALD Trump has said he ordered that two nuclear submarines be deployed in response to 'highly provocative' comments by a senior Russian official. Trump did not say whether he meant nuclear-powered or nuclear-armed submarines. He also did not elaborate on the locations, which are kept secret by the US military. The United States and Russia control the vast majority of the world's nuclear weaponry, and Washington keeps nuclear-armed submarines on patrol as part of its so-called nuclear triad of land, sea and air-launched weapons. 'Based on the highly provocative statements of the Former President of Russia, Dmitry Medvedev…, I have ordered two Nuclear Submarines to be positioned in the appropriate regions, just in case these foolish and inflammatory statements are more than just that,' Trump posted on his Truth Social platform. 'Words are very important, and can often lead to unintended consequences, I hope this will not be one of those instances.' Trump did not refer specifically to what Medvedev had said to prompt the highly unusual public display of nuclear sabre-rattling. On Monday, Medvedev harshly criticised Trump's threat of new sanctions against Russia over the continuing invasion of Ukraine. Advertisement Accusing Trump of 'playing the ultimatum game,' he posted on X that Trump 'should remember' that Russia is a formidable force. 'Each new ultimatum is a threat and a step towards war. Not between Russia and Ukraine, but with his own country,' the Russian official said. Medvedev is currently deputy chairman of Russia's Security Council and a vocal proponent of President Vladimir Putin's war in Ukraine – and generally antagonistic relations with the West. He served one term as president between 2008-2012, effectively acting as a placeholder for Putin, who was able to circumvent constitutional term limits and remain in de facto power. - © AFP 2025 Want to know more about what's happening in Ukraine and why? Check out our FactCheck Knowledge Bank for essential reads and guides to finding good information online. Visit Knowledge Bank
